Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

Corporate giants from Amazon to CVS are investing billions into primary-care practices. It’s part of a sweeping shift in U.S. healthcare to a more value-based model. Here’s what that means for doctors ...

Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented semaglutide drugs exclusively. Compounding is the practice of ...

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--MEDISCA has officially begun accepting orders for its long-awaited thyroid active pharmaceutical ingredient (thyroid API), creating a consistent supply for ...

DUBLIN--(BUSINESS WIRE)--The "Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration ...

Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented semaglutide drugs ...

The CDMO Sector Holds a Core Position in the Pharmaceutical Industry As a major part of the outsourcing pharmaceutical service industry, CDMOs support pharmaceutical companies across the entire chain, ...